Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10859MR)

This product GTTS-WQ10859MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Melanoma, Neuroblastoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10859MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12793MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ13198MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ5190MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ15089MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ8589MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ1222MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ6351MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ15448MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW